Latest News & Successes

Parsity Group hire David MacKenzie as a Partner.

The Parsity Group team are excited to announce the recent appointment of David MacKenzie as Partner into our business. This is a key appointment as Parsity Group continues to expand its search offering globally for companies within the generics, biosimilars and specialty pharmaceuticals industries.

Dave will be working with existing and future clients as well as supporting the overall business in its expansion plans over the coming years. Dave brings approximately 15 years of recruitment industry experience, including the last 9+ years at Sandoz/Novartis in a global search role which included hiring from VP to board including various C-level appointments.

On taking up his new position, Dave remarks: “I am delighted to have joined the Parsity Group team and to be a part of the next stage of growth for the business. I look forward to the opportunities this role will give me to develop professionally, and I am excited to work alongside a really experienced and dynamic group of people.”

Dave is already meeting with our existing partners and developing new relationships for future international search projects so if you would like to arrange a meeting, please contact him at david.mackenzie@parsitygroup.com

To find out more about our team, www.parsitygroup.com

Parsity Group successfully appoint Christoph Stoller as President & Business Head Europe for Glenmark Pharmaceuticals.

London, United Kingdom: Parsity Group are pleased to announce their successful partnership with Glenmark Pharmaceuticals to secure Christoph Stoller as President & Business Head Europe, effective 15th November 2021.

Glenmark Pharmaceuticals recently announced the expansion of its executive team with the appointment of Christoph Stoller as its President and Business Head Europe

A mandated pan-Europe executive search was undertaken by Parsity Group in preparation for what is set to be a transformative period for Glenmark Pharmaceuticals in the region. Well respected pharma leader, Christoph Stoller, arrives from Teva Pharmaceuticals where he was most recently Region Cluster Head Germany & Austria. At Glenmark Pharmaceuticals he will spear head the continued expansion of the company’s operations in Europe.

Having started on the 15th November 2021, he will be based in Germany. Mr Stoller brings an extensiveand relevant track record within the pharmaceutical sector going back over 20 years, which will prove invaluable as Glenmark Pharmaceuticals ramps up it’s growth from both a portfolio and geographical perspective.

President, Business Head Europe, Christoph Stoller commented:

“I enjoyed the experience working with Parsity Group. Dan Nathan is a very experienced executive head-hunter who has successfully guided me through the entire process, from the first contact until contract signature. Hands-on and highly supportive. I would always work with Parsity Group again”.

About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical companywith presence across generics, specialty and OTC businesses and with operations in over 50countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology.It ranks among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings,2020, from Informa’s Generics Bulletin). The company has been listed on the Dow JonesSustainability Index (DJSI), under the category of emerging markets for the third consecutive year ina row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarksglobally with only the top ranked companies in terms of Corporate Sustainability within eachindustry being featured in the index. For more information, visit , www.glenmarkpharma.com